Sunday, 15 April 2012

Variquel 1mg powder and solvent for solution for injection





1. Name Of The Medicinal Product



Variquel 1 mg powder and solvent for solution for injection


2. Qualitative And Quantitative Composition



Each vial of powder contains:



1 mg terlipressin acetate equivalent to 0.85 mg terlipressin.



1 ml of reconstituted solution contains 0.2 mg terlipressin acetate.



For a full list of excipients, see section 6.1.



3. Pharmaceutical Form



Powder and solvent for solution for injection



White to off white solid powder and a clear colourless solution.



4. Clinical Particulars



4.1 Therapeutic Indications



Treatment of bleeding oesophageal varices



4.2 Posology And Method Of Administration




The administration of terlipressin serves the emergency care for acute bleeding oesophageal varices until endoscopic therapy is available. Afterwards the administration of terlipressin for the treatment of oesophageal varices is usually an adjuvant therapy to the endoscopic haemostasis.


Adults



Initially 1



Depending on the patient's body weight the dose can be adjusted as follows:



- Weight less than 50 kg: 1 mg.



- Weight 50 kg to 70 kg: 1.5 mg.



- Weight exceeding 70 kg: 2 mg.



After the initial injection, the dose can be reduced to 1 mg every 4 to 6 hours.



The approximate value for the maximum daily dose of Variquel is 120 μg/kg body weight.



The therapy is to be limited to 2 – 3 days in adaptation to the course of the disease.



Variquel is dissolved with the accompanying solvent and is applied intravenously. The intravenous injection should be given during the period of one minute. For further dilution see section 6.6.



Elderly



Variquel should only be used with caution in patients over 70 years (see section 4.4).



Children and adolescents



Variquel is not recommended in children and adolescents due to insufficient experience on safety and efficacy (see section 4.4)



Renal insufficiency



Variquel should only be used with caution in patients with chronic renal failure (see section 4.4).



Hepatic insufficiency



A dose adjustment is not required in patients with liver failure.



4.3 Contraindications



Hypersensitivity to the active substance or to any of the excipients.



4.4 Special Warnings And Precautions For Use



Variquel should only be used with caution and under strict monitoring of the patients in the following cases:



• septic shock



• bronchial asthma, respiratory deficiencies



• uncontrolled hypertension



• cerebral or peripheral vascular diseases



• cardiac arrhythmias



• coronary deficiencies or previous myocardial infarction



• chronic renal insufficiency



• elderly patients> 70 years as experience is limited in this group



• pregnancy (see section 4.6).



Also hypovolaemic patients often react with an increased vasoconstriction and atypical cardiac reactions.



Due to the weak antidiuretic effect of terlipressin (only 3% of the antidiuretic effect of native vasopressin) especially patients with already disturbed electrolyte metabolism should be monitored for a possible hyponatraemia and hypokalaemia.



In principle the use of the product should be confined to specialist supervision in units with facilities for regular monitoring of the cardiovascular system, haematology and electrolytes.



In emergency situations which require an immediate treatment before sending the patient to a hospital symptoms of hypovolaemia have to be considered.



Terlipressin has no effect on arterial bleeding.



To avoid local necrosis at the injection site, the injection must be administered intravenously.



Skin Necrosis:



During post-marketing experience several cases of cutaneous ischemia and necrosis unrelated to the injection site (see section 4.8) have been reported. Patients with peripheral venous hypertension or morbid obesity seem to have a greater tendency to this reaction. Therefore, extreme caution should be exercised when administering terlipressin in these patients.



Torsade de pointes:



During clinical trials and post-marketing experience, several cases of QT interval prolongation and ventricular arrhythmias including "Torsade de pointes" have been reported (see section 4.8). In most cases, patients had predisposing factors such as basal prolongation of the QT interval, electrolyte abnormalities (hypokalemia, hypomagnesemia) or medications with concomitant effect on QT prolongation. Therefore, extreme caution should be exercised in the use of terlipressin in patients with a history of QT interval prolongation, electrolytic anormalities, concomitant medications that can prolong the QT interval, such as class IA and III antiarrhythmics, erythromycin, certain antihistamines and tricyclic antidepressants or medications that can cause hypokalaemia or hypomagnesemia (e.g. some diuretics) (see section 4.5).



Particular caution should be exercised in the treatment of children, adolescents and elderly patients, as experience is limited and there is no data available regarding dosage recommendation in these special patient categories.



After reconstitution with the accompanying solvent, this medicinal product contains less than 1 mmol (23 mg) of sodium per 5 ml, i.e. essentially "sodium-free".



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



Terlipressin increases the hypotensive effect of non-selective β-blockers on the portal vein. The reduction in heart rate and cardiac output caused by the treatment can be attributed to the inhibition of the reflexogenic activity of the heart through the vagus nerve as a result of increased blood pressure. Concomitant treatment with drugs known to induce bradycardia (e.g. propofol, sufentanil) can cause severe bradycardia.



Terlipressin can trigger ventricular arrhythmias including "Torsade de pointes" (see sections 4.4 and 4.8). Therefore, extreme caution should be exercised in the use of terlipressin in patients with concomitant medications that can prolong the QT interval, such as class IA and III antiarrhythmics, erythromycin, certain antihistamines and tricyclic antidepressants or medications that may cause hypokalaemia or hypomagnesemia (e.g. some diuretics).



4.6 Pregnancy And Lactation



Pregnancy



The use of terlipressin is not recommended during pregnancy as it has been shown to cause uterine contractions and increased intrauterine pressure in early pregnancy and may decrease uterine blood flow. Terlipressin may have harmful effects on pregnancy and foetus. Spontaneous abortion and malformation has been shown in rabbits after treatment with terlipressin (see section 5.3).



Variquel should therefore only be used at vital indication on a case by case decision especially in the first trimester, when bleeding cannot be controlled with endoscopic therapy.



Breastfeeding



It is not known whether terlipressin is excreted in human breast milk. The excretion of terlipressin in milk has not been studied in animals. A risk to the suckling child cannot be excluded. A decision on whether to continue/discontinue breast



4.7 Effects On Ability To Drive And Use Machines



No studies on the effects on the ability to drive and use machines have been performed.



4.8 Undesirable Effects



The assessment of undesirable effects is based on the following frequencies:



very common (>1/10)



common (>1/100 to <1/10)



uncommon (>1/1.000 to <1/100)



rare (>1/10.000 to <1/1.000)



very rare (<1/10.000)



not known (cannot be estimated from the available data)



Treatment of bleeding oesophageal varices with Variquel (1 mg intravenously and more) may be accompanied by the following adverse reactions:



Metabolism and nutrition disorders



Uncommon: hyponatraemia



Very rare: hyperglycaemia



Nervous system disorders



Common: headache



Uncommon: triggering of a convulsive disorder



Very rare: stroke



Cardiac disorders



Common: ventricular and supra-ventricular arrhythmia, bradycardia, signs of ischaemia in the ECG



Uncommon: Angina pectoris, acute hypertension rise, in particular in patients already suffering from hypertension (generally, it decreases spontaneously), atrial fibrillation, ventricular extrasystoles, tachycardia, chest pain, myocardial infarction, fluid overload with pulmonary oedema



Very rare: myocardial ischemia



Not known: cardiac failure, Torsade de Pointes



Vascular disorders



Common: hypertension, hypotension, peripheral ischaemia, peripheral vasoconstriction, facial pallor



Uncommon: intestinal ischaemia, peripheral cyanosis, hot flushes



Respiratory, thoracic and mediastinal disorders



Uncommon: pain in the chest, bronchospasm, respiratory distress, respiratory failure



Rare: dyspnoea



Gastrointestinal disorders



Common: transient abdominal cramps, transient diarrhoea



Uncommon: transient nausea, transient vomiting



Skin and subcutaneous tissue disorders



Common: paleness



Uncommon: lymphangitis



Not known: Skin necrosis unrelated to the site of administration



Reproductive system and breast disorders



Common: abdominal cramps (in women)



Pregnancy, puerperium and perinatal conditions



Not known: uterine constriction, decreased uterine blood flow



General disorders and administration site conditions:



Uncommon: local cutaneous necrosis



During clinical trials and post-marketing experience, several cases of QT interval prolongation and ventricular arrhythmias including "Torsade de pointes" have been reported (see sections 4.4 and 4.5).



During post-marketing experience, several cases of cutaneous ischemia and necrosis unrelated to the injection site have been reported (see section 4.4).



4.9 Overdose



The recommended dose should not be exceeded in any case, since the risk of severe circulatory adverse effects is dose-dependent.



An acute hypertensive crisis, especially in patients with recognized hypertension can be controlled with a vasodilator-type alpha-blocker, e.g. 150 microgram clonidine intravenously.



Bradycardia requiring treatment should be treated with atropine.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Pharmacotherapeutic group: Systemic hormonal preparations, posterior pituitary lobe hormones, vasopressin and analogues



ATC-Code: H01BA04



Terlipressin inhibits portal hypertension with simultaneous reduction of blood circulation in portal vessels. Terlipressin contracts smooth oesophageal muscle with consecutive compression of oesophageal varices.



The inactive pre-hormone terlipressin slowly releases bioactive lysine



Specific effects of terlipressin are assessed as follows:



Gastrointestinal system:



Terlipressin increases the tone of vascular and extravascular smooth muscle cells. The increase in arterial vascular resistance leads to decrease of splanchnic hypervolemia. The decrease of the arterial blood supply leads to reduction of pressure in the portal circulation. Intestinal muscles contract concomitantly which increases intestinal motility. The muscular wall of the esophagus also contracts which leads to closure of experimentally induced varices.



Kidneys:



Terlipressin has only 3% antidiuretic effect of the native vasopressin. This residual activity is of no clinical significance. Renal blood circulation is not significantly effected in normovolemic condition. Renal blood circulation is increased, however, under hypovolemic condition.



Blood pressure:



Terlipressin induces a slow haemodynamic effect which lasts 2



Heart:



All studies reported that no cardio



Uterus:



Terlipressin causes significant decrease in myometrial and endometric blood flow.



Skin:



The vasoconstrictive effect of terlipressin causes significant decrease in blood circulation of the skin. All studies reported obvious paleness on face and body.



In conclusion, the main pharmacological properties of terlipressin are its haemodynamic effects and its effects on smooth muscle. The centralization effect under hypovolemic condition is a desired side effect in patients with bleeding oesophageal varices.



5.2 Pharmacokinetic Properties



After bolus intravenous injection terlipressin elimination follows second order kinetics. Plasma half



5.3 Preclinical Safety Data



Preclinical data reveal no special hazard for humans based on conventional studies of single- and repeat-dose toxicity, and genotoxicity. At doses relevant to humans, the only effects observed in animals were those attributed to the pharmacological activity of terlipressin.



Adverse reactions observed in animal studies with possible relevance to clinical use were as follows:



Due to its pharmacological effect on smooth muscles Variquel may induce abortion in the first trimester.



An embryo-fetal study in rats demonstrated no adverse effects of terlipressin. In rabbits abortions occurred, probably related to maternal toxicity, and there were ossification anomalies in a small number of fetuses and a single isolated case of cleft palate.



No carcinogenicity studies have been performed with terlipressin.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Each vial of powder contains:



Mannitol



Acetic acid (for pH adjustments)



Each solvent ampoule contains:



Sodium chloride



Water for injections



6.2 Incompatibilities



This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.



6.3 Shelf Life



Unopened: 18 months



After reconstitution with solvent ampoule: Use immediately.



From a microbiological point of view, the product should be used immediately.



6.4 Special Precautions For Storage



Do not store above 25°C.



Keep the vial in the outer carton in order to protect from light. For storage of the reconstituted medicinal product, see section 6.3.



6.5 Nature And Contents Of Container



Powder:



Colourless, type I glass vials, closed with bromobutyl rubber stopper and sealed with aluminium flip-off cap



Each vial contains 11 mg powder.



Solvent:



Colourless, type I glass ampoules, sealed by fusion



Each ampoule contains 5 ml solvent.



Pack sizes:



1 vial with powder and 1 ampoule of solvent



5 vials with powder and 5 ampoules of solvent



Not all pack sizes may be marketed.



6.6 Special Precautions For Disposal And Other Handling



Reconstitute the powder only in the solvent provided.



Preparation of injection



The entire contents of the solvent ampoule should be slowly added to the powder vial and the vial rolled gently until the powder is completely dissolved. The powder should dissolve within 10 seconds. A clear colourless solution results.



A further dilution to 10 ml with sterile sodium chloride 9 mg/ml (0.9 %) solution for injection is possible.



For single use only. Discard any unused solution.



The solution should be inspected visually for particles and discolouration prior to administration.



Do not use Variquel if you notice



- that the powder does not dissolve in the accompanying solvent



- that the solution discolours after dissolving the powder.



Any unused product or waste material should be disposed of in accordance with local requirements.



7. Marketing Authorisation Holder



IS Pharmaceuticals Limited



Office Village, Chester Business Park



Chester



CH4 9QZ



United Kingdom



8. Marketing Authorisation Number(S)



PL 13538/0019



9. Date Of First Authorisation/Renewal Of The Authorisation



03/06/2009



10. Date Of Revision Of The Text



August 2010




Saturday, 14 April 2012

Lasix



Generic Name: Furosemide
Class: Loop Diuretics
VA Class: CV702
CAS Number: 54-31-9



  • Furosemide is a potent diuretic that given in excessive amounts may induce a profound diuresis with water and electrolyte depletion.133 e Careful medical supervision is required; dosage selection and titration should be adjusted to the individual patient’s needs.133 e (See Dosage and Administration.)




Introduction

A sulfonamide, loop-type diuretic and antihypertensive agent.133 e


Uses for Lasix


Edema


Management of edema associated with CHF, hepatic cirrhosis, and renal disease (e.g., nephrotic syndrome).133 e


Considered a diuretic of choice for most patients with CHF.131


IV management of acute pulmonary edema (in combination with oxygen and a cardiac glycoside).150


Hypertension


Management of hypertension (alone or in combination with other classes of antihypertensive agents).100 101 109 124 127 133 144


One of several preferred initial therapies in hypertensive patients with CHF or renal disease.100 101 109 124 127 144


Can be used as monotherapy for initial management of uncomplicated hypertension; however, thiazide diuretics are preferred by JNC 7.100 101 124 127 142 143 144


Lasix Dosage and Administration


General


Edema



  • Careful etiologic diagnosis should precede the use of any diuretic.e




  • Hospitalization of the patient during initiation of therapy is advisable, especially for patients with hepatic cirrhosis and ascites or chronic renal failure.133 e




  • Most experts state that all patients with symptomatic CHF who have evidence for, or a prior history of, fluid retention generally should receive diuretic therapy in conjunction with moderate sodium restriction (≤3 g of sodium daily), an ACE inhibitor, and usually a β-blocker, with or without a cardiac glycoside.131




  • In prolonged diuretic therapy, intermittent use of the drug (e.g., on 2–4 consecutive days each week) may be advisable.e



Hypertension



  • Monitor BP carefully, especially during initial therapy.133




  • If added to regimen of a patient receiving another antihypertensive agent, reduce dosage of preexisting therapy by at least 50% initially to avoid severe hypotension; additional dosage adjustment may be required.133



Administration


Administer orally, IV, or IM.133 150


Oral Administration


Administer orally once (preferably in the morning)e or twice daily .133


For ease of administration and maximum dosage flexibility in children, consider use of oral solution preparation.151


IV Administration


For solution and drug compatibility information, see Compatibility under Stability.


IV administration may be used in emergency clinical circumstances when a rapid onset of diuresis is desired, or in patients unable to take oral medication or those with impaired GI absorption; replace with oral therapy as soon as possible.133 150 e


Consider the potential risks, when using large parenteral doses; monitor patient closely.105 107


Dilution

For IV infusion, dilute in 5% dextrose, 0.9% sodium chloride, or lactated Ringer’s injection and adjust pH to >5.5.150 e


Whenever possible, use vials instead of ampuls to prepare large doses to prevent large quantities of glass particles from entering the solutions.e If ampuls must be used, consider filtering through a sterile membrane filter before use to remove any particles that may be present.e


Rate of Administration

For direct IV injection, administer slowly over a period of 1–2 minutes.150 e


If high-dose parenteral furosemide therapy is necessary, the manufacturer recommends that the drug be administered as a controlled infusion at a rate not exceeding 4 mg/minute in adults.150 e


Dosage


Individualize dosage according to patient’s requirements and response; titrate dosage to gain maximum therapeutic effect while using the lowest possible effective dosage.e (See Boxed Warning.)


Pediatric Patients


Edema

Oral

2 mg/kg administered as a single dose.103 104 105 107 108 133 If necessary, increase in increments of 1 or 2 mg/kg every 6–8 hours103 104 105 107 108 to a maximum of 6 mg/kg.103 133 Generally not necessary to exceed individual doses of 4 mg/kg or a dosing frequency of once or twice daily.104 Use minimum effective dosage for maintenance therapy.133


IV or IM

1 mg/kg administered as a single IM or IV injection.103 104 105 106 107 108 150 If necessary for resistant forms of edema, the initial dose may be increased by 1 mg/kg103 104 105 108 no more often than every 2 hours until the desired effect has been obtained or up to a maximum dosage of 6 mg/kg.103 Adequate response usually is obtained with individual parenteral doses of 1 mg/kg.104 105 107 108


Acute Pulmonary Edema

IV or IM

1 mg/kg administered as a single IM or IV injection.103 104 105 106 107 108 150 If necessary for resistant forms of edema, the initial dose may be increased by 1 mg/kg103 104 105 108 no more often than every 2 hours until the desired effect has been obtained or up to a maximum dosage of 6 mg/kg.103 Adequate response generally obtained with 1 mg/kg.104 105 107 108


Hypertension†

Oral

Initially, 0.5–2 mg/kg given once or twice daily.149 Increase as necessary up to a maximum of 6 mg/kg daily.149


Adults


Edema

Oral

20–80 mg given as a single dose, preferably in the morning.133 e If needed, repeat same dose 6–8 hours later or increase dose by 20- to 40-mg increments and give no sooner than 6–8 hours after last dose until desired diuretic response (including weight loss) is obtained.133 e May titrate carefully up to 600 mg daily in severe cases.133


The effective dose may be given once or twice daily thereafter, or, in some cases, by intermittent administration on 2–4 consecutive days each week.133 e Dosage may be reduced for maintenance therapy.e


IV or IM

20–40 mg given as a single IM or IV injection.150 e If needed, repeat same dose 2 hours later or increase dose by 20-mg increments and give no sooner than every 2 hours until the desired diuretic response is obtained.150 Effective dosages may then be given once or twice daily.150


Acute Pulmonary Edema

IV

40 mg given as a single IV injection.150 If needed, an 80-mg dose may be given 1 hour after the initial dose.150


Hypertension

Oral

40 mg twice daily.133 If desired BP not attained, consider adding other antihypertensive agents.133


Usual dosage recommended by JNC 7: 10–40 mg twice daily.127 144


Prescribing Limits


Pediatric Patients


Edema

Oral

Maximum of 6 mg/kg.103 133


IV or IM

Maximum of 6 mg/kg in infants and children; do not exceed 1 mg/kg daily in premature infants.150


Hypertension†

Oral

Maximum 6 mg/kg daily.149


Adults


Edema

Oral

Maximum of 600 mg daily.133


Special Populations


Renal Impairment


Higher doses may be required for patients with acute or chronic renal failure.e


Hypertension

Higher doses may be required for patients with acute or chronic renal failure.e


Oral

Use of ≥3 antihypertensive agents usually is required to achieve a target BP <130/80 mm Hg.144


Cautions for Lasix


Contraindications



  • Anuria.133




  • Known hypersensitivity to furosemide or any ingredient in the formulation.133



Warnings/Precautions


Warnings


Hepatic Effects

Sudden alterations of electrolyte balance in patients with cirrhosis may precipitate hepatic coma; use with caution in patients with hepatic cirrhosis and ascites.133


Do not initiate therapy in patients with hepatic coma or electrolyte depletion until the basic condition is improved.133 Therapy in such patients is best initiated in the hospital with careful monitoring of clinical status and electrolyte balance.133


Renal Effects

If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, discontinue the drug.133 150


Sensitivity Reactions


Anaphylaxis

Anaphylaxis (e.g., urticaria, angioedema, hypotension) within 5 minutes after IV administration reported.102


Systemic Lupus Erythematosus

Possible exacerbation or activation of systemic lupus erythematosus.133 150


Sulfonamide Sensitivity

Patients sensitive to sulfonamides may show allergic reactions to furosemide.e


Photosensitivity

Photosensitivity may occur.133


Major Toxicities


Ototoxicity

Risk of tinnitus, reversible or permanent hearing impairment increased following IV or IM administration, especially at high dosages,133 e after too-rapid administration,133 in patients with severely impaired renal function, and/or in patients receiving other ototoxic drugs (e.g., aminoglycosides).133 e (See Specific Drugs under Interactions.)


If high-dose IV therapy is indicated, administer by slow IV infusion (e.g., at a rate not exceeding 4 mg/minute in adults).133 150


General Precautions


Fluid, Electrolyte, and Cardiovascular Effects

Excessive diuresis may cause dehydration and blood volume reduction with circulatory collapse and possibly vascular thrombosis and embolism, particularly in elderly patients.133 (See Boxed Warning.)


Risk of orthostatic hypotension, especially with brisk diuresis.133 150 151 May be aggravated by concomitant use with alcohol, barbiturates, or narcotics.133 151 e


Risk of hypokalemia, especially with brisk diuresis, inadequate oral electrolyte intake, when cirrhosis is present, or during concomitant use of corticosteroids or ACTH.133 150 Concomitant therapy with digitalis may exaggerate metabolic effects of hypokalemia, especially myocardial effects.133 150


Observe carefully for manifestations of fluid and electrolyte depletion (e.g., dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, arrhythmia, nausea, vomiting).133


Endocrine Effects

Possible increased blood glucose and alterations in glucose tolerance tests (with abnormalities of the fasting and 2-hour postprandial sugar); precipitation of diabetes mellitus rarely reported.133 150 Monitor urine and blood glucose concentrations periodically in patients with diabetes and those suspected of latent diabetes.e


Possible hyperuricemia and precipitation of gout;133 150 use with caution in patients with a history of gout or elevated serum uric acid concentrations.e


Patient Monitoring

Monitor regularly for the possible occurrence of blood dyscrasias, liver or kidney damage, or other idiosyncratic reactions.133 150


Serum electrolytes (particularly potassium), CO2, creatinine and BUN should be determined frequently during the first few months of therapy and periodically thereafter.133 150


Elective Surgery

Discontinue therapy 1 week (oral furosemide) or 2 days (parenteral furosemide) before elective surgery.e


Specific Populations


Pregnancy

Category C.133


Lactation

Distributed into milk.133 Use with caution.133


Pediatric Use

Risk of persistent patent ductus arteriosus (PDA) may be increased in premature neonates with respiratory distress syndrome (RDS) who receive furosemide during the first weeks of life.103 e


Do not exceed dosage of 1 mg/kg per 24 hours in premature neonates with <31 weeks’ postconception age (gestational age at birth plus postnatal age); risk of potentially toxic furosemide plasma concentrations with higher dosages.150


Renal calcification reported in severely premature infants treated with IV furosemide for edema due to PDA and hyaline membrane disease; concomitant chlorothiazide therapy may decrease hypercalciuria and dissolve some calculi.150


Hearing loss reported in neonates; possibly secondary to renal immaturity.103 125 126 150


Oral solutions contain sorbitol; high dosages may cause diarrhea in children.e


Hepatic Impairment

Use with caution.133 e


Renal Impairment

Use with caution.133 e


Common Adverse Effects


Orthostatic hypotension, dizziness, electrolyte imbalance (hyponatremia, hypokalemia, hypochloremia) tinnitus, photosensitivity.133 e


Interactions for Lasix


Specific Drugs





































































Drug



Interaction



Comments



Alcohol



May aggravate orthostatic hypotension133 151 e



Anticonvulsant agents (e.g., phenytoin sodium, phenobarbital)



Possible reduced diuretic effecte



Antidiabetic agents (e.g., insulin, oral agents)



Possible antagonism of hypoglycemic effect as result of hypokalemia133



Observe for possible decreased diabetic control; correct potassium deficit and/or adjust dosage of antidiabetic agente



Antihypertensive agents



Additive antihypertensive effect; orthostatic hypotension may occur133



Reduce dosage of both drugse


Concomitant therapy generally used to therapeutic advantagee



Barbiturates



May aggravate orthostatic hypotension133 151 e



Cardiac glycoside (e.g., digoxin)



Possible electrolyte disturbances (e.g., hypokalemia, hypomagnesemia), increased risk of digitalis toxicity, and/or fatal cardiac arrhythmias e



Monitor electrolytes; correct hypokalemia e



Chloral hydrate



Possible reaction characterized by diaphoresis, flushes, hypertension, and uneasiness in patients with acute MI and CHFe



Consider alternate hypnotic drug (e.g., a benzodiazepine) in patients who require IV furosemidee



Diuretics, loop (e.g., bumetanide, ethacrynic acid, torsemide)



Share similar diuretic mechanisms e



No therapeutic rationale for concomitant usee



Diuretics, potassium- sparing (e.g., amiloride, spironolactone, triamterene)



Possible reduction in potassium loss 133



May be used to therapeutic advantage133



Diuretics, thiazides



Additive diuretic effecte



Use reduced dosage of furosemide when added to existing diuretic regimene



Drugs that cause potassium loss (e.g., corticosteroids, corticotropin, amphotericin B)



Additive hypokalemic effects133 e



Monitor electrolytes; correct hypokalemia 133 e



Indomethacin



Possible decreased diuretic and natriuretic effect133



Monitor closely to determine if desired diuretic and/or hypotensive effect is obtained133



Lithium



Reduced renal clearance of lithium and increased risk of lithium toxicity 133



Avoid concomitant use;133 e if concomitant therapy is necessary, monitor for lithium toxicitye



Narcotics



May aggravate orthostatic hypotension133 151 e



Neuromuscular blocking agents, nondepolarizing (e.g., atracurium besylate, tubocurarine chloride)



Potential for prolonged neuromuscular blockadee



Norepinephrine



Decreased arterial responsive to norepinephrine133



Norepinephrine may still be used effectively133



Ototoxic drugs (e.g., aminoglycoside antibiotics)



Possible additive ototoxic effect, especially in patients with impaired renal function133



Avoid concomitant use except in life-threatening situations133



Salicylates (e.g., aspirin, NSAIAs)



Possible transient reductions in Clcr in patient with chronic renal insufficiencye


Possible weight gain and increased Scr, serum potassium concentrations, and BUN (NSAIAs)133



Monitor for toxicity133



Succinylcholine



May potentiate action of succinylcholine133



Sucralfate



Possible reduced natriuretic and antihypertensive effects133



Do not administer simultaneously; separate administration by ≥2 hours133


Observe closely for desired diuretic and/or antihypertensive effect133



Uricosuric drugs (probenecid, sulfinpyrazone)



Possible antagonism of uricosuric effectse



Monitor serum uric acid concentrationse


Lasix Pharmacokinetics


Absorption


Bioavailability


Mean oral bioavailability of furosemide from commercially available tablets and oral solution is 64% and 60%, respectively.133


Commercially available tablets and oral solution are bioequivalent.133


Onset


Following oral administration, onset of diuresis occurs within 30 minutes to 1 hour; maximal effect after 1–2 hours.133 e


Following IV administration, diuresis occurs within 5 minutes and peaks within 20–60 minutes.150 e


Onset of diuresis after IM administration occurs somewhat later than after IV administration.150


Maximum hypotensive effect may not be apparent until after several days of therapy.e


Duration


Diuretic effect persists 6–8 hours following oral administration and approximately 2 hours following IV administration.133 150 e


Food


Food does not appear to affect diuretic effect.e


Special Populations


In patients with severely impaired renal function, the diuretic response may be prolonged.e


Distribution


Extent


Crosses the placenta and is distributed into milk.e


Plasma Protein Binding


Approximately 95% bound to plasma proteins (mainly albumin) in both normal and azotemic patients.133 e


Elimination


Metabolism


Metabolized in the liver to the defurfurylated derivative, 4-chloro-5-sulfamoylanthranilic acid.e


Elimination Route


Rapidly excreted in urine by glomerular filtration and by secretion from the proximal tubule.e


Approximately 50% of an oral dose and 80% of an IV or IM dose are excreted in urine within 24 hours; 69–97% of these amounts is excreted in the first 4 hours.150 e The remainder of the drug is eliminated by nonrenal mechanisms including degradation in the liver and excretion of unchanged drug in the feces.e


Half-life


Biphasic;e terminal half-life is approximately 2 hours.133


Special Populations


Hepatic or renal impairment prolongs the elimination half-life of the drug.e


In patients with marked renal impairment without liver disease, nonrenal clearance is increased to the extent that up to 98% of the drug is cleared within 24 hours.e


Not removed by hemodialysis.133


Stability


Storage


Oral


Solution or Tablets

Tight, light resistant containers at 15–30°C.133 151


Parenteral


Injection

15–30°C; protect from light.150 Discard unused portion.150


Compatibility


For information on systemic interactions resulting from concomitant use, see Interactions.


Parenteral


Do not mix with strongly acidic solutions (i.e., pH < 5.5), such as those containing ascorbic acid, amrinone, ciprofloxacin, labetalol, tetracycline, milrinone, epinephrine, or norepinephrine, because furosemide may be precipitated.150 e


Solution Compatibilitya
















Compatible



Alcohol 5% and dextrose 5%



Amino acids 4.25%, dextrose 25%



Dextrose 5% in Ringer’s injection, lactated



Dextrose 5% in sodium chloride 0.9%



Dextrose 5, 10, or 20% in water



Invert sugar 10% in Electrolyte #1



Mannitol 20%



Ringer’s injection, lactated



Sodium chloride 0.9%



Sodium lactate (1/6) M



Incompatible



Fructose 10% in water



Invert sugar 10% in Electrolyte #2


Drug Compatibility

















































Admixture Compatibilitya

Compatible



Amikacin sulfate



Aminophylline



Ampicillin sodium



Atropine sulfate



Bumetanide



Calcium gluconate



Cefuroxime sodium



Cimetidine HCl



Dexamethasone sodium phosphate



Diamorphine HCl



Digoxin



Epinephrine HCl



Heparin sodium



Hydrocortisone sodium succinate



Isosorbide dinitrate



Kanamycin sulfate



Lidocaine HCl



Midazolam HCl



Meropenem



Morphine sulfate



Nitroglycerin



Penicillin G



Potassium chloride



Ranitidine HCl



Scopolamine butylbromide



Sodium bicarbonate



Sulphadimidine



Theophylline



Tobramycin sulfate



Incompatible



Buprenorphine HCl



Chlorpromazine HCl



Diazepam



Dobutamine HCl



Erythromycin lactobionate



Isoproterenol HCl



Meperidine HCl



Metoclopramide HCl



Papaveretum



Prochlorperazine edisylate



Promethazine HCl



Variable



Amiodarone HCl



Gentamicin sulfate



Hydrocortisone sodium succinate



Verapamil HCl































































































Y-Site Compatibilitya

Compatible



Allopurinol sodium



Amifostine



Amikacin sulfate



Amphotericin B cholesteryl sulfate complex



Aztreonam



Bivalirudin



Bleomycin sulfate



Cefepime HCl



Ceftazidime



Cisplatin



Cladribine



Cyclophosphamide



Cytarabine



Dexmedetomidine HCl



Docetaxel



Doxorubicin HCl liposome injection



Epinephrine HCl



Etoposide phosphate



Fentanyl citrate



Fludarabine phosphate



Fluorouracil



Foscarnet sodium



Granisetron HCl



Heparin sodium



Hetastarch in lactated electrolyte injection (Hextend)



Hydrocortisone sodium succinate



Hydromorphone HCl



Indomethacin sodium trihydrate



Kanamycin sulfate



Leucovorin calcium



Linezolid



Lorazepam



Melphalan HCl



Meropenem



Methotrexate sodium



Mitomycin



Nitroglycerin



Norepinephrine bitartrate



Paclitaxel



Piperacillin sodium–tazobactam sodium



Potassium chloride



Propofol



Ranitidine HCl



Remifentanil HCl



Sargramostim



Sodium nitroprusside



Tacrolimus



Tirofiban HCl



Teniposide



Thiotepa



Tirofiban



Tobramycin sulfate



Vitamin B complex with C



Incompatible



Amsacrine



Azithromycin



Chlorpromazine HCl



Ciprofloxacin



Clarithromycin



Diltiazem HCl



Droperidol



Esmolol HCl



Fenoldopam mesylate



Filgrastim



Fluconazole



Gatifloxacin



Gemcitabine HCl



Gentamicin sulfate



Hydralazine HCl



Idarubicin HCl



Levofloxacin



Metoclopramide HCl



Midazolam HCl



Milrinone lactate



Nicardipine HCl



Ondansetron HCl



Quinidine gluconate



Thiopental sodium



Vecuronium bromide



Vinblastine sulfate



Vincristine sulfate



Vinorelbine tartrate



Variable



Amiodarone HCl



Dobutamine HCl



Dopamine HCl



Doxorubicin HCl



Famotidine



Labetalol HCl



Meperidine HCl



Morphine sulfate


ActionsActions



  • Inhibits primarily the absorption of sodium and chloride not only in the proximal and distal tubules but also in the ascending limb of the loop of Henle.133 e Does not inhibit carbonic anhydrase and is not an aldosterone antagonist.e




  • Mechanism of hypotensive effect not definitively determined but presumed to result from decreased plasma volume.e




  • Induces greater diuresis and electrolyte loss than with thiazides or most other diuretics except ethacrynic acid.e




  • Possesses some renal vasodilator effect; renal vascular resistance decreases and renal blood flow increases following administration.e



Advice to Patients



  • Risks associated with excessive fluid loss or electrolyte imbalance.133




  • Potential for postural hypotension; importance of rising slowly from a seated position.133




  • Importance of discussing dietary measures and supplementation to prevent or correct hypokalemia.133




  • Importance of informing patients with diabetes mellitus that blood glucose and urine glucose concentrations may increase.133 e




  • Importance of informing patients of possible photosensitivity.133 e




  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs (e.g., appetite suppressants, cold remedies) as well as any concomitant illnesses.133 e




  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.133 e




  • Importance of informing patients of other important precautionary information.133 e (See Cautions.)



Preparations


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.


* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name





















































Furosemide

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Oral



Solution



40 mg/5 mL*



Furosemide Solution (with alcohol 0.2% and sorbitol)



Roxane



10 mg/mL*



Furosemide Solution



Morton Grove, Roxane



Tablets



20 mg*



Furosemide Tablets



IVAX, Mylan, Qualitest, Roxane, Sandoz, UDL



Lasix



Sanofi-Aventis



40 mg*



Furosemide Tablets



IVAX, Mylan, Qualitest, Roxane, Sandoz, UDL



Lasix (scored)



Sanofi-Aventis



80 mg*



Furosemide Tablets



Mylan, Qualitest, Roxane, Sandoz, UDL



Lasix



Sanofi-Aventis



Parenteral



Injection



10 mg/mL*



Furosemide Injection



American Pharmaceutical Partners, American Regent, Hospira, IMS


Comparative Pricing


This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.


Furosemide 10MG/ML Solution (MORTON GROVE PHARMACEUTICALS): 120/$15.99 or 360/$35.97


Furosemide 10MG/ML Solution (ROXANE): 60/$17.99 or 120/$25.98


Furosemide 20MG Tablets (SANDOZ): 100/$13.99 or 200/$18.97


Furosemide 40MG Tablets (SANDOZ): 100/$13.99 or 200/$19.96


Furosemide 80MG Tablets (SANDOZ): 30/$12.99 or 60/$15.98


Lasix 20MG Tablets (SANOFI-AVENTIS U.S.): 30/$24.25 or 90/$45.92


Lasix 40MG Tablets (SANOFI-AVENTIS U.S.): 30/$25.99 or 90/$54.91


Lasix 80MG Tablets (SANOFI-AVENTIS U.S.): 30/$35.99 or 90/$85.97



Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.


The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions April 2010. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.


† Use is not currently included in the labeling approved by the US Food and Drug Administration.




References


Only references cited for selected revisions after 1984 are available electronically.



100. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The 1984 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1984; 144:1045-57. [IDIS 184763] [PubMed 6143542]



101. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The 1980 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1980; 140:1280-5. [IDIS 375724] [PubMed 6775608]



102. Hansbrough JR, Wedner HJ, Chaplin DD et al. Anaphylaxis to intravenous furosemide. J Allergy Clin Immunol. 1987; 80:538-41. [IDIS 235418] [PubMed 3668117]



103. Hoechst-Roussel. Lasix (furosemide) injection, oral solution, and tablets prescribing information (dated 1994 Oct). In: Physicians’ desk reference. 50th ed. Montvale NJ: Medical Economics Company Inc; 1996:1240-2.



104. Engle MA, Lewy JE, Lewy PR et al. The use of furosemide in the treatment of edema in infants and children. Pediatrics. 1978; 62:811-8. [IDIS 118470] [PubMed 724325]



105. Baliga R, Lewy JE. Pathogenesis and treatment of edema. Pediatr Clin North Am. 1987; 34:639-48. [PubMed 3588044]



106. Repetto HA, Lewy JE, Braudo JL et al. The renal functional response to furosemide in children with acute glomerulonephritis. J Pediatr. 1972; 80:660-6. [PubMed 5015080]



107. Lewy JE. Diuretics in infancy. Controversies Nephrol. 1981; 27:33-44.



108. Lewy JE, Moel DI. Pathogenesis and management of edema in the newborn. Clin Perinatol. 1975; 2:117-23. [PubMed 1102212]



109. 1988 Joint National Committee. The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1988; 148:1023-38. [IDIS 242588] [PubMed 3365073]



110. Lardinois CK, Neuman SL. The effects of antihypertensive agents on serum lipids and lipoproteins. Arch Intern Med. 1988; 148:1280-8. [IDIS 242671] [PubMed 2897834]



111. Holland OB, Pool PE. Metabolic changes with antihypertensive therapy of the salt-sensitive patient. Am J Cardiol. 1988; 61:53-9H.



112. Weinberger MH. Diuretics and their side effects: dilemma in the treatment of hypertension. Hypertension. 1988; 11(Suppl II):II-16-20.



113. Ames R. Effects of diuretic drugs on the lipid profile. Drugs. 1988; 36(Suppl 2):33-40. [IDIS 248276] [PubMed 3063504]



114. Lasser NL, Grandits G, Caggiula AW et al. Effects of antihypertensive therapy on plasma lipids and lipoproteins in the Multiple Risk Factor Intervention Trial. Am J Med. 1984; 76(Suppl 2A):52-66. [IDIS 182290] [PubMed 6367451]



115. Bloomgarden ZT, Ginsberg-Fellner F, Rayfield EJ et al. Elevated hemoglobin A1c and low-density lipoprotein cholesterol levels in thiazide-treated diabetic patients. Am J Med. 1984; 77:823-7. [IDIS 192589] [PubMed 6496535]



116. Gluck Z, Baumgartner G, Weidmann P et al. Increased ratio between serum beta- and alpha-lipoproteins during diuretic therapy: an adverse effect? Clin Sci Mol Med Suppl. 1978; 4:325-8s.



117. Ames RP, Hill P. Antihypertensive therapy and the risk of coronary heart disease. J Cardiovasc Pharmacol. 1982; 4(Suppl 2):S206-12. [PubMed 6177958]



118. Ames RP, Hill P. Improvement of glucose tolerance and lowering of glycohemoglobin and serum lipid concentrations after discontinuance of antihypertensive drug treatment. Circulation. 1982; 65:899-904. [IDIS 150695] [PubMed 7042109]



119. Perola P, Lehto H, Lammintausta R et al. Metabolic effects of furosemide and the combination of furosemide and triamterene. Curr Ther Res. 1985; 37:545-53.



120. Weinberger MH. Antihypertensive therapy and lipids: evidence, mechanisms, and implications. Arch Intern Med. 1985; 145:1102-5. [IDIS 200606] [PubMed 2860883]



121. Gerlag PGG, van Meijel JJM. High-dose furosemide in the treatment of refractory congestive heart failure. Arch Intern Med. 1988; 148:286-91. [IDIS 238227] [PubMed 3341836]



122. Weidmann P, Gerber A. Effects of treatment with diuretics on serum proteins. J Cardiovasc Pharmacol. 1984; 6(Suppl 1):S260-8. [PubMed 6204152]


Thursday, 12 April 2012

trifluoperazine


Generic Name: trifluoperazine (trye floo oh PER a zeen)

Brand Names: Stelazine


What is trifluoperazine?

Trifluoperazine is an anti-psychotic medication in a group of drugs called phenothiazines (FEEN-oh-THYE-a-zeens). It works by changing the actions of chemicals in your brain.


Trifluoperazine is used to treat anxiety or psychotic disorders such as schizophrenia.


Trifluoperazine may also be used for purposes not listed in this medication guide.


What is the most important information I should know about trifluoperazine?


Stop using this medication and call your doctor at once if you have twitching or uncontrollable movements of your eyes, lips, tongue, face, arms, or legs. These could be early signs of dangerous side effects. Trifluoperazine is not for use in psychotic conditions related to dementia. Trifluoperazine may cause heart failure, sudden death, or pneumonia in older adults with dementia-related conditions. Do not use trifluoperazine if you have liver disease, brain damage, bone marrow depression, a blood cell disorder (such as low platelets or low red or white blood cell counts), or if you are also using large amounts of alcohol or medicines that make you sleepy. Do not use if you are allergic to trifluoperazine or other phenothiazines.

Before you take trifluoperazine, tell your doctor about all of your medical conditions, and if you have ever had a serious side effect while using trifluoperazine or similar medicines. Also, tell your doctor about all other medications you use.


What should I discuss with my healthcare provider before taking oral trifluoperazine?


Trifluoperazine is not for use in psychotic conditions related to dementia. Trifluoperazine may cause heart failure, sudden death, or pneumonia in older adults with dementia-related conditions. Do not use trifluoperazine if you have liver disease, brain damage, bone marrow depression, a blood cell disorder (such as low platelets or low red or white blood cell counts), or if you are also using large amounts of alcohol or medicines that make you sleepy. Do not use if you are allergic to trifluoperazine or other phenothiazines such as chlorpromazine (Thorazine), fluphenazine (Permitil), perphenazine (Trilafon), prochlorperazine (Compazine, Compro), promethazine (Adgan, Pentazine, Phenergan), or thioridazine (Mellaril).

To make sure you can safely take trifluoperazine, tell your doctor if you have any of these other conditions:



  • heart disease high blood pressure, or angina (chest pain);




  • severe asthma, emphysema, or other breathing problem;




  • glaucoma;




  • a history of seizures;




  • adrenal gland tumor (pheochromocytoma);




  • Parkinson's disease;




  • enlarged prostate or urination problems;




  • low levels of calcium in your blood (hypocalcemia);




  • past or present breast cancer; or




  • if you are pregnant.



Tell your doctor if you will be exposed to extreme heat or cold, or to insecticide poisons while you are taking trifluoperazine.


Taking antipsychotic medication during the last 3 months of pregnancy may cause problems in the newborn, such as withdrawal symptoms, breathing problems, feeding problems, fussiness, tremors, and limp or stiff muscles. However, you may have withdrawal symptoms or other problems if you stop taking your medicine during pregnancy. If you become pregnant while taking trifluoperazine, do not stop taking it without your doctor's advice. Trifluoperazine can pass into breast milk and may harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby. Talk with your doctor before giving this medication to a child who has been ill with a fever or flu symptoms.

How should I take trifluoperazine?


Take exactly as prescribed by your doctor. Do not take in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label. Your doctor may occasionally change your dose to make sure you get the best results.


Call your doctor if your symptoms do not improve, or if they get worse while taking trifluoperazine.

If you need to have an x-ray or CT scan of your spinal column using a dye that is injected into a vein, you may need to temporarily stop taking trifluoperazine. Be sure the doctor knows ahead of time that you are using this medication.


Do not stop using trifluoperazine suddenly after long-term use, or you could have unpleasant withdrawal symptoms. Ask your doctor how to avoid withdrawal symptoms when you stop using trifluoperazine. Store at room temperature away from moisture, heat, and light.

See also: Trifluoperazine dosage (in more detail)

What happens if I miss a dose?


Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention or call the Poison Help line at 1-800-222-1222. Overdose symptoms may include dry mouth, constipation, bloating or stomach cramps, extreme drowsiness or feeling restless and agitated, changes in heart rate, fever, fainting, and seizure (convulsions).

What should I avoid while taking trifluoperazine?


This medication may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert. Avoid getting up too fast from a sitting or lying position, or you may feel dizzy. Get up slowly and steady yourself to prevent a fall. Drinking alcohol can increase certain side effects of trifluoperazine. Avoid exposure to sunlight or tanning beds. Trifluoperazine can make you sunburn more easily. Wear protective clothing and use sunscreen (SPF 30 or higher) when you are outdoors.

Trifluoperazine side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop using trifluoperazine and call your doctor at once if you have a serious side effect such as:

  • twitching or uncontrollable movements of your eyes, lips, tongue, face, arms, or legs;




  • tremor (uncontrolled shaking), drooling, trouble swallowing, problems with balance or walking;




  • feeling restless, jittery, or agitated;




  • very stiff (rigid) muscles, high fever, sweating, confusion, fast or uneven heartbeats, feeling like you might pass out;




  • decreased night vision, tunnel vision, watery eyes, increased sensitivity to light;




  • seizure (black-out or convulsions);




  • nausea and stomach pain, skin rash, and jaundice (yellowing of the skin or eyes);




  • urinating less than usual or not at all;




  • pale skin, easy bruising or bleeding, fever, sore throat, flu symptoms;




  • joint pain or swelling with fever, swollen glands, muscle aches, chest pain, vomiting, unusual thoughts or behavior, and patchy skin color; or




  • slow heart rate, weak pulse, fainting, slow breathing (breathing may stop).



Less serious side effects may include:



  • dizziness, drowsiness, anxiety, sleep problems (insomnia);




  • blurred vision, headache;




  • dry mouth, stuffy nose;




  • constipation;




  • breast swelling or discharge;




  • missed menstrual periods;




  • weight gain, swelling in your hands or feet; or




  • impotence, trouble having an orgasm.



This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


Trifluoperazine Dosing Information


Usual Adult Dose for Schizophrenia:

Oral:
Initial dose: 2 to 5 mg twice a day (small or emaciated patients should be started on the lower dosage).
Maintenance dose: 15 to 20 mg/day, occasionally up to 40 mg/day or more in some cases. Optimum therapeutic dosage levels should be reached within 2 or 3 weeks.

IM:
For patients requiring prompt control of severe symptoms:
1 to 2 mg (1/2 to 1 mL) by deep IM injection every 4 to 6 hours as needed. Dosages exceeding 6 mg/24 hours are rarely necessary, and only in very exceptional cases should the dosage exceed 10 mg/24 hours.

Injections should not be given at intervals of less than 4 hours because of a possible cumulative effect.

Usual Adult Dose for Anxiety:

For treatment of nonpsychotic anxiety:
1 or 2 mg orally twice daily, not to exceed 6 mg/day or for longer than 12 weeks.

Usual Geriatric Dose for Schizophrenia:

Oral:
Initial dose: 2 mg twice a day.
Maintenance dose: 15 mg/day.
Optimum therapeutic dosage levels should be reached within 2 or 3 weeks.

IM:
For patients requiring prompt control of severe symptoms:
1 mg (1/2 mL) by deep IM injection every 4 to 6 hours as needed. Injections should not be given at intervals of less than 4 hours because of a possible cumulative effect.

In general, dosages in the lower range are sufficient for most elderly patients. Since they appear to be more susceptible to hypotension and neuromuscular reactions, such patients should be observed closely.

Usual Geriatric Dose for Anxiety:

For treatment of nonpsychotic anxiety:
1 mg orally twice daily for no more than 12 weeks.

Usual Pediatric Dose for Schizophrenia:

6 to 12 years (patients who are hospitalized or under close supervision):

Oral:
Initial dose: 1 mg once or twice a day.
Dosage may be increased gradually until symptoms are controlled or until side effects become troublesome. While dosages exceeding 15 mg/day are generally not necessary, some older children with severe symptoms may require higher dosages.

IM:
There has been little experience with the use of trifluoperazine injection in children. However, if it is necessary to achieve rapid control of severe symptoms, 1 mg (1/2 mL) of the drug may be administered IM once or twice a day.

Dosage should be adjusted to the weight of the child and severity of the symptoms.


What other drugs will affect trifluoperazine?


Cold or allergy medicine, sedatives, narcotic pain medicine, sleeping pills, muscle relaxers, and medicine for seizures, depression or anxiety can interact with trifluoperazine and cause medical problems or increase side effects. Tell your doctor if you regularly use any of these medicines, or any other anti-psychotic medications.

Also tell your doctor if you are taking any of the following medicines:



  • atropine (Atreza, Sal-Tropine);




  • lithium (Eskalith, Lithobid);




  • phenytoin (Dilantin);




  • an antibiotic;




  • birth control pills or hormone replacement estrogens;




  • a blood thinner such as warfarin (Coumadin, Jantoven);




  • certain asthma medications or bronchodilators;




  • a diuretic (water pill);




  • drugs to treat high blood pressure or a prostate disorder, such as alfuzosin (Uroxatral), doxazosin (Cardura), prazosin (Minipress), terazosin (Hytrin), tamsulosin (Flomax);




  • incontinence medications;




  • insulin or diabetes medications you take by mouth;




  • medication for nausea, vomiting, or motion sickness;




  • medications to treat or prevent malaria;




  • medications used for general anesthesia;




  • medicines used to prevent organ transplant rejection;




  • numbing medicine such as lidocaine or Novocain;




  • a stimulant or ADHD medication;




  • ulcer or irritable bowel medications; or




  • medicines to treat Parkinson's disease, restless leg syndrome, or pituitary gland tumor (prolactinoma).



This list is not complete and there are many other drugs that can interact with trifluoperazine. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor. Keep a list of all your medicines and show it to any healthcare provider who treats you.



More trifluoperazine resources


  • Trifluoperazine Side Effects (in more detail)
  • Trifluoperazine Dosage
  • Trifluoperazine Use in Pregnancy & Breastfeeding
  • Drug Images
  • Trifluoperazine Drug Interactions
  • Trifluoperazine Support Group
  • 3 Reviews for Trifluoperazine - Add your own review/rating


  • Trifluoperazine MedFacts Consumer Leaflet (Wolters Kluwer)

  • Trifluoperazine Hydrochloride Monograph (AHFS DI)



Compare trifluoperazine with other medications


  • Anxiety
  • Schizophrenia


Where can I get more information?


  • Your pharmacist can provide more information about trifluoperazine.

See also: trifluoperazine side effects (in more detail)


Wednesday, 11 April 2012

Isosorbide Mononitrate Tablets 10mg, 20mg, 40mg (Actavis UK Ltd)






Isosorbide Mononitrate Tablets 10mg, 20mg and 40mg




  • Please read this leaflet carefully before you start to take your medicine.


  • It tells you some of the more important things you should know.


  • If you want to know more, or you are not sure about anything, ask your doctor or pharmacist.




What’S In Your Medicine


Isosorbide Mononitrate Tablets are circular white to off-white uncoated tablets which come in three strengths, containing 10mg; 20mg; or 40mg of the active ingredient isosorbide mononitrate.


They also contain: lactose magnesium stearate, maize starch, polyvidone; E460 (10mg and 40mg only)


Isosorbide Mononitrate Tablets are available in pack sizes of 56s.


Isosorbide mononitrate is one of a group of medicines called nitrate vasodilators. These drugs relax the muscle layer in the blood vessel wall of the heart. This reduces strain on the heart by making it easier to pump blood.



MA holder/Manufacturer:



Actavis

Barnstaple

EX32 8NS

UK





About Your Medicine


The name of your medicine is Isosorbide mononitrate which is the generic (common) name. Your doctor may have given you this medicine before from another company and it may have looked slightly different. Either brand will have the same effect.


Isosorbide Mononitrate Tablets are used to


  • relieve the pain and frequency of angina attacks.

  • help control certain types of heart failure.



Before Taking Your Medicine


Make sure you have told your doctor if you:


  • are pregnant, plan to become pregnant, or are breast feeding.

  • are sensitive to any of the ingredients in the product or are sensitive to isosorbide dinitrate.

  • have any blood disorders or anaemia.

  • have angina that is caused by an enlarged heart muscle.

  • have glaucoma (increased pressure in the eye).

  • have recently suffered from a head injury or have suffered from bleeding into the brain.

  • have any condition where your blood pressure is very low or your blood is not circulating properly, such as shock.

  • have liver or kidney problems.

  • have an underactive thyroid gland.

  • suffer from very low body temperature (hypothermia) or are malnourished.

  • are taking other medicines such as ACE inhibitors (eg captopril, enalapril), acetylcholine, beta-blockers, histamine or noradrenaline and any others that you have bought without prescription.

If sildenafil, tadalafil or vardenafil (for male erection dysfunction) is used by patients taking nitrate preparations such as Isosorbide Mononitrate Tablets a severe and possibly dangerous fall in blood pressure can occur. This would result in collapse, unconsciousness and could be fatal. You should not take these whilst on Isosorbide Mononitrate Tablets.


You are advised NOT to drink alcohol with this medicine.


If you see another doctor or go into hospital, let them know what medicines you are taking.




Taking Your Medicine


Your doctor has decided the dose which is best for you. Always follow your doctor’s instructions exactly, and those on the pharmacy label. If you do not understand anything, ask your doctor or pharmacist.


The usual dosage(s) are described below:




Indication: Dosage

Adults (including the elderly)

Angina: Initially 20mg twice daily then 20mg two or three times daily. The usual maintenance dosage range is 20-120mg daily.


Congestive heart failure: Usually 20mg two or three times daily (40-60mg). The dosage will depend upon your clinical condition. Your doctor will also usually be treating you with other drugs.



If you have kidney or liver disease you may be given a smaller dose.


These tablets should be taken as instructed swallowed whole after meals, followed by a glass of water. Continue to take them for as long as your doctor tells you to, it may be dangerous to stop without their advice.


If you forget to take a dose, take another as soon as you remember and then your next dose at the usual time. NEVER take two doses at the same time.


If you are elderly, it is particularly important to take this medicine exactly as directed by the doctor.


If you accidentally take more than your prescribed dose, contact your nearest hospital casualty department, or tell your doctor, immediately. Take any remaining tablets and the container with you to give to the doctor.




After Taking Your Medicine


Like many medicines, Isosorbide mononitrate may occasionally cause side-effects in some patients, particularly when you first start taking it. These may include flushing, dizziness, weakness, faintness on standing, dry, flaky skin rashes or fast or rarely slow heart rate. If you have a certain type of brain tumour Isosorbide mononitrate can make your symptoms
worse. Headaches are a common side effect and can be relieved with painkillers, they usually get better after 1-3 weeks of treatment. You should consult your doctor if these effects are troublesome or continue.


If you get any other unusual effects, tell your doctor immediately and seek advice.




Storing Your Medicine


Do not use the tablets after the expiry date shown. Keep the tablets below 25°C in a dry place and in the original packaging.



KEEP THEM IN A SECURE PLACE WHERE CHILDREN CANNOT GET AT OR SEE THEM. REMEMBER, this medicine is for YOU only. NEVER give it to anyone else. It may harm them, even if their symptoms are the same as yours. Unless your doctor tells you to, do not keep medicines that you no longer need - give them back to your pharmacist for safe disposal.



Date of last revision: January 2009




Actavis

Barnstaple

EX32 8NS

UK


50227473